Why GeneDX Stock Is Plummeting Today

GeneDX (NASDAQ: WGS) stock is getting crushed in Tuesday's trading. The biotech company's share price was down 48.7% as of 11 a.m. ET.

GeneDX published its first-quarter results after yesterday's market close, posting sales and earnings for the period that came in far worse than Wall Street had anticipated. Intensifying bearish pressures for the stock, the company also cut its full-year guidance.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

GeneDX recorded a non-GAAP (adjusted) loss of $0.28 per share on sales of roughly $102.3 million in the first quarter. While sales were still up roughly 17% year over year, they came in roughly $10.2 million short of the average Wall Street analyst estimate.

Even worse, the business's adjusted loss per share for the period came in $0.26 higher than the level called for by the average analyst forecast. While exome and genome volume increased 34% year over year, the company faced a $5.5 million sales shortfall stemming from lower-than-expected average reimbursement rates in the category and a $6.5 million shortfall in the company's non-core business lines.

In conjunction with its softer-than-expected Q1 performance, GeneDX cut its full-year guidance. Management is now targeting sales between $475 million and $490 million for the year -- down from its previous target for sales between $540 million and $555 million. Meanwhile, the average analyst estimate had targeted sales of $550 million for the period.

GeneDX's pricing power is looking significantly weaker coming out of its Q1 report. In addition to the softer sales outlook for the year, the company is likely looking at a much lower adjusted profit -- so it's not surprising investors are fleeing the stock today.

Before you buy stock in GeneDx, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GeneDx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $490,864!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,789!*

Now, it’s worth noting Stock Advisor’s total average return is 963% — a market-crushing outperformance compared to 201% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

*Stock Advisor returns as of May 5, 2026.

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Why GeneDX Stock Is Plummeting Today was originally published by The Motley Fool